To further determine whether the enhanced sensitivity to gemcitabine after FOXM1 inhibition correlated with changes in NF-κB activity in pancreatic cancer cells, we compared the status of NF-κB in pancreatic cancer cells using immunoblotting and NF-κB-dependent reporter activity. The gene discussed is NFKB1; the disease is pancreatic neoplasm.